Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up

Candel Therapeutics, Inc.

Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.
Consistent favorable trends in TTBF, TTM, metastasis rate, and TTNT in ITT population.
In intermediate-risk subgroup (85% of patients), 90% reduction in time to metastasis (HR 0.1).
Company plans to submit BLA to FDA in Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.